Back to News
Oct 23, 2025 4:00 AM

Vitrolife AB (publ) - Interim report Q3, 2025: Strong growth in Americas

GOTHENBURG, Sweden, Oct. 23, 2025 /PRNewswire/ --

Third quarter

Sales of SEK 835 (867) million, 3% growth in local currencies and a 4% decrease in SEK, due to a significant currency impact of -7%. Organic growth in local currencies excluding discontinued business* was 5%.

Sales per region, in local currencies, were -2% in EMEA, +4% excluding discontinued business, +11% in Americas and +1% in APAC.

Sales per product group, in local currencies excluding discontinued business, were +7 in Consumables, +8% in Technologies and +3% in Genetics.

Sales per product group, in local currencies, were +4% in Consumables, +8% in Technologies and 0% in Genetics.

Gross margin increased to 58.9% (58.6), explained by a favourable product mix despite negative currency impact.

Earnings before depreciation and amortisation (EBITDA) amounted to SEK 253 (289) million, resulting in an EBITDA margin of 30.3% (33.4), impacted by negative currency effect.

Operating cash ...